NASDAQ
1.77USD
-0.08 (-4.32%)
We have scored 11 news catalysts on enGene Holdings Inc. (ENGN) over the past 12 months. The biggest single-day move next to one of them came May 8, 2026, when ENGN closed −12.8%: “Forward Air Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses”. Coverage across the window leans negative (average ticker sentiment −0.25). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
118.6M
P/E
—
EPS
—
Beta
-0.27
52W range
1.4-12.25
Day range
1.76–1.82
Open
1.81
Prev close
1.85
Volume
565K
Avg volume
1.5M
Dividend
0.00
IPO
2022-02-01
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about enGene Holdings Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ENGN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
